{"entity":{"id":"nct05601726","kind":"trial","name":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","aka":["ODYSSEY"],"tldr":"A phase 1/2 trial of ABD-3001 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Advanced BioDesign, now recruiting.","summary":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients is a phase 1/2 interventional study registered as NCT05601726 by Advanced BioDesign, with 36 participants planned, started 2022-11-08 and due to reach its primary completion in 2026-06. Interventions recorded: ABD-3001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05601726","url":"https://clinicaltrials.gov/study/NCT05601726"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds","aml-older-unfit","mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05601726","phase":"1/2","setting":"First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 As Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy.","sponsor":"Advanced BioDesign","participation":[{"nct":"NCT05601726","source":"https://clinicaltrials.gov/study/NCT05601726","fetchedAt":"2026-10-07T16:53:47.239Z","studySha256":"15daddf65d3e3bfa121184f9455a43118ac28e4f04fd52670f2a8a4ab81c56ff","overallStatus":"RECRUITING","lastUpdatePosted":"2025-01-20","leadSponsor":"Advanced BioDesign","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":36,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["France"]}],"started":"2022-11-08","startedType":"actual","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05601726/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}]}}